BioWorld

Dec. 19, 2007

BioMS Signs $497M Deal With Lilly For SPMS Drug

Shares of BioMS Medical Corp. jumped 38 percent Tuesday after the company unveiled plans to license its Phase III multiple sclerosis drug MBP8298 to Eli Lilly and Co. in a deal potentially worth more than $497 million. (BioWorld Today) Read More

CovX's Peptide-Antibody Bid Attracts Acquisition By Pfizer

Positive Data In Alzheimer's Send EPIX's Shares Soaring

Santaris Raises 20M For LNA-Based Drug Portfolio

ActivBiotics Selling Assets In Wake Of Rifalazil Failure

HGS's Anthrax Drug, ABthrax, Positive In Two Animal Studies

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 18, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld Science

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Maintenance, man: Lilly’s phase III weight trial hits goals

BioWorld

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...